Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 13/20 | 0.70 |
| ▸ | DRD3 | P35462 | 7/20 | 0.48 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2783663 | 0.90 | DRD2 (0.54) | DRD2DRD3HTR6ADRA1DADRA1A | |
| SCHEMBL2784464 | 0.87 | DRD2 (0.52) | DRD2DRD3HTR6LMNAADRA1D | |
| SCHEMBL2781300 | 0.86 | DRD2 (0.54) | DRD2DRD3HTR6LMNAGAA | |
| SCHEMBL5503767 | 0.85 | DRD2 (0.51) | DRD2DRD3HTR6ADRA1DADRA1A | |
| SCHEMBL2784948 | 0.83 | DRD2 (0.47) | DRD2DRD3LMNAGAAADRA1D | |
| SCHEMBL2783260 | 0.82 | DRD2 (0.52) | DRD2DRD3HTR6LMNAGAA | |
| SCHEMBL2782917 | 0.82 | DRD2 (0.77) | DRD2DRD3HTR6ADRA1DADRA1A | |
| SCHEMBL2781703 | 0.81 | DRD2 (0.75) | DRD2DRD3HTR6LMNAADRA1D | |
| SCHEMBL2780625 | 0.81 | DRD2 (0.75) | DRD2DRD3HTR6ADRA1DADRA1A | |
| SCHEMBL2781857 | 0.80 | DRD2 (0.54) | DRD2DRD3HTR6LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256163-A1 | DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | SANIONA AB (DK) | 2010-10-07 | — | — | US | claimed |
| EP-2204363-A1 | New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2010-07-07 | — | — | EP | claimed |
| US-20070149542-A1 | DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | SANIONA AB (DK) | 2007-06-28 | — | — | US | claimed |
| EP-1773772-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2007-04-18 | — | — | EP | claimed |
| WO-2005121087-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2005-12-22 | — | — | WO | claimed |
| US-8314126-B2 | Disubstituted phenylpiperdines/piperazines as modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2012-11-20 | — | — | US | disclosed |
| US-20100256163-A1 | DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | SANIONA AB (DK) | 2010-10-07 | — | — | US | disclosed |
| US-7763639-B2 | Disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-07-27 | — | — | US | disclosed |
| EP-2204363-A1 | New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2010-07-07 | — | — | EP | disclosed |
| US-20070149542-A1 | DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | SANIONA AB (DK) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256163-A1 | DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | DRD2, DRD4, DRD1 | DRD2 1/4885DRD3 4/4885HTR6 95/4885 |
| US-20070149542-A1 | DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | DRD2, DRD4, DRD1 | DRD2 1/4885DRD3 4/4885HTR6 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.